Patients with active Rheumatoid Arthritis and an inadequate response to @ or more non biologic DMARDS were randomized to receive intravenous Rituximab ( @ course consisting of @ infusions of @ mg each - one group , and Etanercept @ mg twice weekly - second group , but both groups with background MTX .